in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
40 <strong>in</strong> <strong>vitro</strong> pharmacology <strong>2011</strong> catalog<br />
❚ glucagon<br />
glucagon - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 1407<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
BioPr<strong>in</strong>t ® profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
[ 125 I]glucagon (0.025 nM)<br />
0.069 nM<br />
glucagon (1 µM)<br />
glucagon (IC 50 : 1.2 nM)<br />
Chicchi, G.G. et al. (1997) J. Biol. Chem., 272: 7765-7769.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
glucagon<br />
cellul ar<br />
Ref. 1839 Agonist effect<br />
Ref. 1840 Antagonist effect<br />
Q 3 weeks<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product cAMP<br />
Detection method HTRF<br />
Agonist effect Control glucagon (100 nM)<br />
Reference glucagon (EC 50 : 0.21 nM)<br />
Antagonist effect Stimulant glucagon (1 nM)<br />
Reference [des-His 1 -Glu 9 ]-glucagon amide<br />
(IC 50 : 2.14 µM)<br />
Chichi, G.G. et al. (1997) J. Biol. Chem., 272: 7765-7769.<br />
cAMP modulation (% of control)<br />
100<br />
50<br />
0<br />
-12 -11<br />
-10 -9 -8 -7 -6 -5<br />
log [agonist] (M)<br />
glucagon<br />
GLP-1(7-37)<br />
GLP-2(1-34)<br />
100<br />
[Solvent] must be kept ≤ 0.3%<br />
50<br />
0<br />
-9 -8 -7 -6 -5 -4 -3<br />
log [antagonist] (M)<br />
[des-His 1 ,Glu 9 ]-<br />
glucagon amide<br />
L168,049<br />
exend<strong>in</strong>-3(9-39)<br />
secret<strong>in</strong><br />
cellul ar<br />
Ref. 2012<br />
Ref. 2014<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
Measured product cAMP<br />
Detection method HTRF<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Agonist effect Control human secret<strong>in</strong> (3 nM)<br />
Reference human secret<strong>in</strong> (EC 50 : 0.07 nM)<br />
Antagonist effect Stimulant human secret<strong>in</strong> (0.3 nM)<br />
Reference unavailable<br />
Ishihara, T. et al. (1991) Embo. J., 10: 1635-1641.<br />
<br />
<br />
-12 -11<br />
-12 -11<br />
-11 -10<br />
-12 -11<br />
<br />
-9 -8 -7 -6 -5 -4<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7<br />
-10 -9 -8 -7 -6 -5<br />
-11 -10<br />
-9 -8 -7 -6 -5<br />
-10 -4<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.3%<br />
-9 -8 -7 -6 -5 -4<br />
-13 -12 -11 -10 -9 -8 -7 -6<br />
<br />
<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4<br />
<br />
❚ For Glutamate and Glyc<strong>in</strong>e assays, see "Other receptors", pp. 86 and 87<br />
<br />
<br />
❚ Glycoprote<strong>in</strong> hormone<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
TSH<br />
cellul ar<br />
Ref. 2237<br />
Ref. 2239<br />
Q 3 weeks<br />
Agonist effect<br />
Antagonist effect<br />
Source<br />
human recomb<strong>in</strong>ant (HEK-293 cells)<br />
Measured product cAMP<br />
Detection method HTRF<br />
Agonist effect Control TSH (10 µM)<br />
Reference TSH (EC 50 : 27.8 nM)<br />
Antagonist effect Stimulant TSH (100 nM)<br />
Reference unavailable<br />
Rapoport, B. et al. (1998) Endocr<strong>in</strong>ol. Rev., 19: 673-716.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
[Solvent] must be kept 0.3%<br />
<br />
<br />
❚ Gonadotroph<strong>in</strong>-releas<strong>in</strong>g hormone<br />
GnRH (LH-RH) - agonist radioligand<br />
Source<br />
rat pituitary gland<br />
Ligand<br />
[ 125 I][D-Trp 6 ]-LH-RH (0.05 nM)<br />
Kd<br />
0.1 nM<br />
Non specific [D-Trp 6 ]-LH-RH (1 µM)<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Reference [D-Trp 6 ]-LH-RH (IC 50 : 0.096 nM)<br />
Ref. 0456<br />
Q 4 weeks<br />
Halmos, G. et al. (1996) Proc. Natl. Acad. Sci. USA, 93: 2398-2402.